Yes. SMART therapy has an excellent long-term safety profile supported by over a decade of clinical trial data involving hundreds of thousands of patients worldwide. The ICS doses used are the same as those in traditional controller therapy — delivered more intelligently, precisely when and where they are needed. Dr. Dixit Kumar Thakur monitors all Pulmovista patients on SMART therapy with regular spirometry and clinical review to ensure optimal dosing over time.